Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Actimid enters phase II trial for prostate cancer

Nov. 3, 2003

Anti-EGFR antibody with ADCC-inducing activity

Oct. 31, 2003

Favrille raises financing to support phase II and III trials of FavId for NHL

Oct. 21, 2003

ACP-2127 advanced into preclinical testing

Oct. 20, 2003

Signal patent describes novel ER modulators for osteoporosis, cancer, etc.

Oct. 16, 2003

Evidence of antitumor activity for Xcellerated T-cells and IL-2 in renal cell carcinoma

Oct. 9, 2003

NeuTec seeks development partners for Mycograb for cancer

Oct. 8, 2003

Expansion of phase III Virulizin trial

Oct. 2, 2003

Telomerase-targeting vaccines in development at GemVax

Oct. 1, 2003

Maxim completes enrollment for phase III trial of Ceplene with IL-2

Sep. 29, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...